74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Iovance Biotherapeutics Inc
Open
SectorHealthcare
3.3 -5.44
Overview
Share price change
24h
Min
3.19
Max
3.55
Income | 5M -79M |
|---|---|
Sales | 15M 74M |
EPS | -0.26 |
Profit margin | -106.602 |
Employees | 838 |
EBITDA | 14M -75M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +510.15% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -524M 1.2B |
|---|---|
Previous open | 8.74 |
Previous close | 3.3 |
News Sentiment
By Acuity
50%
50%
180 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Iovance Biotherapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Iovance Biotherapeutics Inc Forecast
Price Target
By TipRanks
510.15% upside
12 Months Forecast
Average 19.83 USD 510.15%
High 32 USD
Low 6 USD
Based on 13 Wall Street analysts offering 12 month price targets forIovance Biotherapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
180 / 386 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
